Camp4 Therapeutics GAAP EPS of -$0.37 (NASDAQ:CAMP)

Camp4 Therapeutics reported a Q3 GAAP EPS of -$0.37, missing estimates by $0.37. The company had $124.5M in cash and equivalents as of September 30, 2026, up from $109.5M at the end of 2025. The earnings report was released on November 6, 2026.

Original reporting
Published Nov 6, 2026, 9:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CAMP
Bearish
high confidence
Mentioned
$CAMP
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CAMPBearishMed
01

Why it matters

Earnings miss may trigger short‑term sell‑off but cash reserves mitigate immediate liquidity concerns.

02

Market read

Earnings miss for a small‑cap biotech; relevant for traders with exposure to the sector.

03

What to watch

Cash balance of $124.5M provides runway; upcoming data releases could offset the miss.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Camp4 Therapeutics is a Nasdaq‑listed biotech focused on oncology therapeutics.

Company-level read

Ticker impact

$CAMPBearishHigh confidence
Context

Camp4 Therapeutics reported Q3 GAAP EPS of -$0.37, a miss versus expectations.

Expected impact

likely pressure as the market prices in the EPS miss

Evidence & confidence

Negative earnings surprise typically triggers sell‑offs in small‑cap biotech stocks.

Market effects

May weigh on other small‑cap biotech peers awaiting earnings.

Limited to U.S. biotech investors.

Low global impact.

Counterpoint

If the miss is already priced in, the stock could rebound on short‑covering.

Key entities

  • Camp4 Therapeutics Corporation

    Biotech firm reporting Q3 results.

Related articles

$CAMPHighAI 8/10

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

CAMP4 Therapeutics received EU approval for its Phase 1/2 trial of CMP-002, a treatment for SYNGAP1-related disorder, adding to recent clearances in the UK, Australia, and Argentina. The company plans to start the ASCEND trial in 4Q 2026, aiming to provide a first-in-class therapy for a rare genetic disorder with no current approved treatments.

$CAMPMedAI 8/10

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics (Nasdaq: CAMP) received UK authorization to include sites in its Phase 1/2 trial for CMP-002, a potential treatment for SYNGAP1-related disorder. The company plans to start the trial in 4Q 2026, following clearances in Australia and Argentina. CMP-002 aims to restore SYNGAP protein levels, with no approved therapies currently available for this rare disorder.

$CAMPMedAI 8/10

CAMP4 Q2 Net Loss Widens; On Track To Advance CMP-002 Into Phase 1/2 Trial In Q4 2026

CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.

$CAMPMed

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate

Camp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua